Updated on 9 December 2013
The team's findings hold great promise for the potential use of Elabela as a therapeutic molecule for cardiovascular disease to be used in cardiac repair and control of hypertension. As some people might have a harmful copy of the Elabela gene in their genetic make-up, sequencing and screening for this particular gene in the general population might also help to detect predisposition to heart anomalies before the disease progresses.
Dr Bruno Reversade said, "The human genome has been sequenced over a decade ago. That we can still find anonymous hormones charms me. There are a still a few more to discover but not for long."
Prof Birgitte Lane, executive director of IMB, said, "This discovery shows great promise for the development of targeted therapies for heart disease and blood pressure control in the future. It is an excellent example of how basic research can lead to surprising and unexpected findings that may change and refine medical practice."
Prof Hong Wan Jin, executive director, IMCB, said, "I am very pleased with Bruno's achievement as it reflects the synergy of collaboration and joint efforts among various research institutes in Singapore."